Serum C7 Levels Predict Liver Complications in Fatty Liver Disease

Serum C7 Levels Identify Higher Risk of Severe Liver Events

Elevated serum complement C7 levels indicate an increased likelihood of liver complications in metabolic dysfunction-associated steatotic liver disease (MASLD). Researchers at Shinshu University in Japan evaluated this blood marker across multiple patient groups to assess its predictive value. The findings appeared in the medical journal JHEP Reports.

People with serum C7 concentrations at or above 140 micrograms per milliliter (μg/mL) faced a higher incidence of liver-related events (LREs). In statistical models adjusting for other clinical factors, high C7 levels carried a hazard ratio of 4.54 with a 95% confidence interval of 1.49 to 13.82. This association held across independent cohorts totaling thousands of individuals.

Validation Across Three Independent Patient Cohorts

The study evaluated complement C7 across three separate patient populations to test consistency. These cohorts included 430 individuals with biopsy-confirmed MASLD, 120 patients evaluated with vibration-controlled transient elastography (VCTE), and 4,486 participants from the UK Biobank repository. Across all groups, serum C7 measurements correlated with fibrosis stage and liver stiffness.

In the VCTE cohort, C7 achieved an area under the receiver operating characteristic curve (AUROC) of 0.90 for detecting liver complications. This score surpassed several established blood panels and calculation scores evaluated in the same cohort.

• Fibrosis-4 (FIB-4) index: 0.85
• Autotaxin: 0.84
• Aspartate aminotransferase to platelet ratio index (APRI): 0.77
• FibroScan-aspartate aminotransferase (FAST) score: 0.75
• Aspartate aminotransferase-to-alanine aminotransferase ratio (AAR): 0.67

Cellular Mechanism in Hepatic Stellate Cells

Single-nucleus ribonucleic acid (RNA) sequencing showed that activated hepatic stellate cells act as a primary source of C7 in fibrotic tissue. Complement C7 localized directly to fibrotic regions. The researchers noted that C7 expression aligned with pathways governing extracellular matrix (ECM) organization.

Cell culture experiments provided additional functional data. In cultured human LX-2 hepatic stellate cells, researchers used small interfering ribonucleic acid (siRNA) to knock down C7 expression. This targeted knockdown decreased the expression of structural ECM genes, including LAMA2, LAMB1, and COL6A3.

Clinical Context for Metabolic Risk Assessment

Staging liver fibrosis remains a central challenge in metabolic care because conventional biopsies carry physical risks and high financial costs. Current noninvasive tools such as ultrasound elastography and composite blood scores offer practical alternatives but can produce ambiguous results. Identifying accurate circulating proteins can help clinicians refine risk assessments before advanced complications develop.

For individuals managing metabolic conditions, discussing noninvasive fibrosis screening with a healthcare professional can clarify personal risk profiles. Routine clinical blood panels already track basic liver enzymes, but specialized biomarkers like C7 may eventually offer more specific risk stratification if adopted into commercial testing.

Current Study Limitations and Research Needs

The published findings do not prove that complement C7 directly causes liver damage or disease progression. Differences in patient characteristics between the test cohorts could also influence how broadly these numbers apply in diverse clinical populations. The laboratory cell experiments require follow-up in living animal models to confirm causal biology.

Long-term prospective trials must evaluate whether tracking changes in C7 over time improves clinical outcomes. For now, serum C7 remains strictly an investigational research metric. Patients evaluating their liver health should consult a doctor regarding standard noninvasive tests currently available in clinical practice.